EU, method C preference [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2019-10-11 08:25 (560 d 02:42 ago) – Posting: # 20683
Views: 3,084

Hi all,

I remember having heard EU regulators mention preference for method C out of consideration for the type I error. But I can't seem to find a presentation from anyone saying so. Do you know, do one of you experts have a link or a presentation by a regulator where this was stated?

Many thanks.

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,429 posts in 4,479 threads, 1,512 registered users;
online 11 (0 registered, 11 guests [including 5 identified bots]).
Forum time: Friday 11:07 UTC (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5